


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A pseudoerythromycin derivative represented by the formula [I],



wherein R_1 and R_2 are same or different and each represents H, alkyl, alkynyl, acyl, or sulfonyl, ~~in which these groups may optionally have substituents, and Me indicates methyl, wherein~~ when R_1 is Me or i-Pr, R_2 is not H or Me, R_2 is not H, Me, or i-Pr, and wherein Me is methyl.

2. (canceled)

3. (original) A compound according to claim 1 which is bis-de(3'-N-methyl)-3'-N-ethyl-8, 9-anhydro-pseudoerythromycin A 6, 9-hemiketal or salt thereof.


4. (original) A compound according to claim 1 which is bis-de(3'-N-methyl)-3', 3'-N, N-diethyl-8, 9-anhydro-pseudoerythromycin A 6, 9-hemiketal or salt thereof.

5. (original) A compound according to claim 1 which is bis-de(3'-N-methyl)-3'-N-propyl-8, 9-anhydro-pseudoerythromycin A 6, 9-hemiketal or salt thereof.

6. (original) A compound according to claim 1 which is bis-de(3'-N-methyl)-3', 3'-N, N-dipropyl-8, 9-anhydro-pseudoerythromycin A 6, 9-hemiketal or salt thereof.

7-10. (canceled)

11. (currently amended) A pseudoerythromycin derivative represented by the formula [III],




wherein R₃ is [[O or]] NOH, and Me indicates methyl.

12-22. (canceled)

23. (currently amended) A method for the differentiation-induction of a monocyte to a macrophage ~~in a patient in need of treatment thereof~~, comprising:

~~administering to~~ treating said ~~patient~~ monocyte with an effective amount of a pseudoerythromycin derivative represented by the formula [I],



wherein R₁ and R₂ are same or different and each represents H, alkyl, alkynyl, acyl, or sulfonyl, in which these groups may optionally have substituents, and Me indicates methyl, wherein when R₁ is Me or I-Pr, R₂ is not H.

24-25. (canceled)